Doyle Thomas James
- SEC CIK
- 0001910331
In the past year, 3 open-market sale filings worth $151.8K and no purchases.
Current role at each company
- KURA Kura Oncology, Inc.SVP, Finance & Accountingas of Jan 27, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $151.8K
- 3 filings
- Net
- −$151.8K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Doyle Thomas James as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 (view filing) | Jan 27 | Same day | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −7.14K | $8.46 | −$60.4K | −4.7%145.2K after | 5 lots |
| Nov 14, 2025 (view filing) | Nov 14 | Same day | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −4.54K | $11.18 | −$50.7K | −3.4%130.3K after | |
| Sep 29, 2025 (view filing) | Sep 29 | Same day | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −4.54K | $8.94 | −$40.6K | −4.0%109.8K after | |
| Jan 28, 2025 (view filing) | Jan 28 | Same day | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −4.95K | $7.87 | −$38.9K | −5.3%88.2K after | 4 lots |
| Jan 31, 2024 (view filing) | Jan 29 | 2 days | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −2.32K | $17.80 | −$41.3K | −4.6%48.1K after | 3 lots |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −1.55K | $13.89 | −$21.5K | −8.4%16.8K after | 2 lots |